Linked Life Data

12525513

Source:http://linkedlifedata.com/resource/pubmed/id/12525513

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2003-1-14
pubmed:abstractText
Endostatin is the first endogenous angiogenesis inhibitor to enter clinical trials. Laboratory investigations with endostatin have indicated broad antitumor activity coupled with remarkably low toxicity. A phase I trial of recombinant human endostatin was designed to evaluate toxicity and explore biologic effectiveness in patients with refractory solid tumors.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Collagen, http://linkedlifedata.com/resource/pubmed/chemical/Endostatins, http://linkedlifedata.com/resource/pubmed/chemical/Endothelial Growth Factors, http://linkedlifedata.com/resource/pubmed/chemical/Fibroblast Growth Factor 2, http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Signaling Peptides..., http://linkedlifedata.com/resource/pubmed/chemical/Lymphokines, http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factors
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
223-31
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:12525513-Adult, pubmed-meshheading:12525513-Aged, pubmed-meshheading:12525513-Angiogenesis Inhibitors, pubmed-meshheading:12525513-Blotting, Western, pubmed-meshheading:12525513-Collagen, pubmed-meshheading:12525513-Diagnostic Imaging, pubmed-meshheading:12525513-Dose-Response Relationship, Drug, pubmed-meshheading:12525513-Endostatins, pubmed-meshheading:12525513-Endothelial Growth Factors, pubmed-meshheading:12525513-Female, pubmed-meshheading:12525513-Fibroblast Growth Factor 2, pubmed-meshheading:12525513-Humans, pubmed-meshheading:12525513-Infusions, Intravenous, pubmed-meshheading:12525513-Intercellular Signaling Peptides and Proteins, pubmed-meshheading:12525513-Lymphokines, pubmed-meshheading:12525513-Male, pubmed-meshheading:12525513-Middle Aged, pubmed-meshheading:12525513-Neoplasms, pubmed-meshheading:12525513-Neovascularization, Pathologic, pubmed-meshheading:12525513-Peptide Fragments, pubmed-meshheading:12525513-Recombinant Proteins, pubmed-meshheading:12525513-Tissue Distribution, pubmed-meshheading:12525513-Vascular Endothelial Growth Factor A, pubmed-meshheading:12525513-Vascular Endothelial Growth Factors
pubmed:year
2003
pubmed:articleTitle
Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors.
pubmed:affiliation
Department of Medicine, Section of Medical Oncology and University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Medical School, Madison, 53792, USA.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Clinical Trial, Phase I